Vassiliki A. Boussiotis

CTLA-4 regulates cell cycle progression during a primary immune response.

Blockade of B7/CD28 in mixed lymphocyte reaction cultures results in the generation of alternatively activated macrophages, which suppress T-cell responses.

CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells.

Antigen-specific and persistent tuberculin anergy in a cohort of pulmonary tuberculosis patients from rural Cambodia.

IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL.

Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells.

RIAM, an Ena/VASP and Profilin ligand, interacts with Rap1-GTP and mediates Rap1-induced adhesion.

Common gamma chain-signaling cytokines promote proliferation of T-cell acute lymphoblastic leukemia.

CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy.

Rap1-GTP is a negative regulator of Th cell function and promotes the generation of CD4+CD103+ regulatory T cells in vivo.

Rap1 regulation of RIAM and cell adhesion.

CD28 costimulation mediates transcription of SKP2 and CKS1, the substrate recognition components of SCFSkp2 ubiquitin ligase that leads p27kip1 to degradation.

Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications.

A pathway regulated by cell cycle inhibitor p27Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance.

Twisted gastrulation (Tsg) is regulated by Tob and enhances TGF-beta signaling in activated T lymphocytes.

Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution.

CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors.

Interleukin-4 stimulates proliferation and growth of T-cell acute lymphoblastic leukemia cells by activating mTOR signaling.

Control and regulation of peripheral tolerance in allergic inflammatory disease: therapeutic consequences.

The Nore1B/Mst1 complex restrains antigen receptor-induced proliferation of naïve T cells.

Tob, a member of the APRO family, regulates immunological quiescence and tumor suppression.

The cyclin dependent kinase inhibitor (R)-roscovitine prevents alloreactive T cell clonal expansion and protects against acute GvHD.

RIAM regulates the cytoskeletal distribution and activation of PLC-gamma1 in T cells.

IL-1β-mediated signals preferentially drive conversion of regulatory T cells but not conventional T cells into IL-17-producing cells.

Rap1A regulates generation of T regulatory cells via LFA-1-dependent and LFA-1-independent mechanisms.

Rap1-GTP-interacting adaptor molecule (RIAM) protein controls invasion and growth of melanoma cells.

Molecular and functional heterogeneity of T regulatory cells.

Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.

Runx1 and Runx3 are involved in the generation and function of highly suppressive IL-17-producing T regulatory cells.

PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A.

Rap1-interacting adapter molecule (RIAM) associates with the plasma membrane via a proximity detector.

RIAM (Rap1-interacting adaptor molecule) regulates complement-dependent phagocytosis.

PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.

The role of IL-17-producing Foxp3+ CD4+ T cells in inflammatory bowel disease and colon cancer.

The cyclin dependent kinase inhibitor (R)-roscovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors.

Biochemical signaling of PD-1 on T cells and its functional implications.

The role of the thymus in T-cell immune reconstitution after umbilical cord blood transplantation.

Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma.

PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation.

Cell-specific PD-L1 expression in DLBCL.

Regulation of T Cell Differentiation and Function by EZH2.

Clinical significance of T cell metabolic reprogramming in cancer.

Corrigendum: Regulation of T Cell Differentiation and Function by EZH2.

Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults.

Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.

The role of metabolic reprogramming in T cell fate and function.

Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses.

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies.

The adaptor molecule RIAM integrates signaling events critical for integrin-mediated control of immune function and cancer progression.

JAK3-mediated phosphorylation of EZH2: a novel mechanism of non-canonical EZH2 activation and oncogenic function.

Feeling stressed? It might be your T cells.

Immunotherapies for malignant glioma.

Possible reactivation of chromosomally integrated human herpesvirus 6 after treatment with histone deacetylase inhibitor.

Publisher Correction: Feeling stressed? It might be your T cells.

Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy.